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Propolis and its flavonoid compounds cause
cytotoxicity on human urinary bladder transitional cell
carcinoma in primary culture
Abstract
Background and purpose: The flavonoids present in propolis are con-
sidered to be a rich source of chemopreventive agents since they have various
therapeutic biological activities. This study was carried out to find whether
propolis and its polyphenolic/flavonoid compounds may induce cytotoxicity
in primary culture of human urinary bladder transitional cell carcinoma
(TCC) cells as compared to normal urinary bladder epithelial cells.
Material and Methods: Pieces of TCC or normal bladder epithelial tis-
sue were collected by transurethral surgery from patients in different stages
(grade G1, G2, G3) of TCC. Single cell suspension from pieces of either
TCC or normal bladder epithelial tissue was prepared according to standard
laboratory procedure. Incubation for cytotoxicity testing was carried out in
RPMI-1640 medium with 20% FCS at 37°C and with 5% CO2 with or
without different concentration (50, 150, 300 µg/ml) of test components.
Results:. The cytotoxicity of two preparations of propolis (water and
ethanolic extract of propolis; WSDP or EEP) and its polyphenolic com-
pounds (caffeic acid, naringin, chrysin, and quercetin) was determined us-
ing trypan blue exclusion assay. The findings suggest that EEP is the most
effective in inhibition of urinary bladder TCC cell proliferation as com-
pared to WSDP or single flavonoids derived from propolis. All test compo-
nents showed no cytotoxic effect on normal epithelial cells.
Conclusions: The result of this study may have considerable impact on
the potential use of EEP as an adjuvant to surgery to suppress or prevent tu-
mor recurrence in urinary bladder since only a few anti-cancer drugs have
been effective in tumor control. As immunomodulation by BCG has been
used to improve the results of surgery it is likely that propolis preparation
(EEP) as an immunomodulating compound may be a substitute for myco-
bacterial treatment since propolis preparation or its polyphenolic compo-
nents have expressed no side effect after treatment. However, the exact can-
cer chemoprevention mechanisms of propolis have to be elucidated.
INTRODUCTION
Transitional cell carcinoma is the most important cancer of the uri-nary tract and occurs in the renal pelvis, ureter, urinary bladder,
and urethra. Bladder cancer is the forth most common cancer among




1Department of Animal Physiology,
Faculty of Science, University of Zagreb
Rooseveltov trg 6, Zagreb, Croatia
2General Hospital, Urology Department
Me{trovi}eva b.b., 42000 Vara`din, Croatia
Correspondence:
Nada Or{oli}
Department of Animal Physiology
Faculty of Science, University of Zagreb
Rooseveltov trg 6, 10 000 Zagreb, Croatia
E-mail: norsolic@yahoo.com
Key words: Propolis, Flavonoids, Human
urinary bladder cancer, Cytotoxicity, Primary
culture
received January 9, 2008.
PERIODICUM BIOLOGORUM UDC 57:61
VOL. 111, No 1, 113–121, 2009 CODEN PDBIAD
ISSN 0031-5362
Original scientific paper
bladder cancer occurs about twice as often in males than
females. The highest incidence of cancer of the urinary
bladder is observed in developed countries, with the ex-
ception of Japan and Russia (e.g. North America 29.2/
100,000 vs. Japan 8.8/100,000). However, the occurrence
of urinary bladder cancer among Japanese emigrants in
the USA, beyond the second generation, is twice that
seen in those remaining in Japan (2). North Africa is well
known as a high-risk area for squamous-cell carcinoma
of the urinary bladder, which is certainly related to the
presence of urinary schistosomiasis.
Neoplasms in the urinary-tract epithelium possess
several biological characteristics, such as multistage and
multifocal carcinogenesis (3). The majority of bladder
tumors (90%) have been found to be transitional cell car-
cinoma (TCC) where variable morphology, natural history
and prognosis demonstrate that it is not single disease
but occurs in three distinct forms, each possessing char-
acteristic features such as carcinoma in situ; low-grade
papillary, non-invasive; and high grade, invasive malig-
nancy (4-6). Moreover, a high recurrence rate (50–70%)
of superficial urinary bladder tumors, even after curative
transurethral resection (TUR) has often been reported
(7). These successive, recurrent tumors may increase in
their histological grade, and more than 15% of patients
suffer a progression to muscle-invasive disease, with sub-
sequent poor prognosis (8, 9).
A number of anti-cancer drugs have been used, main-
ly via local instillation into the urinary bladder, as an
adjuvant to surgery to suppress or prevent tumor recur-
rence in urinary bladder but only a few anti-cancer drugs
have been effective in tumor control. Thereafter, a new
additional modality is required to achieve more satisfac-
tory clinical control for this malignancy.
Large amounts of epidemiological data have support-
ed the inverse relation between the consumption of fruits
and vegetables and the incidence of cancer. Thus, a num-
ber of environmental causes have been identified for uri-
nary bladder cancer, including such dietary factors as
low vitamin A intake, infrequent consumption of carrots,
milk and cruciferous vegetables, and high consumption
of meat, animal fat and coffee. The flavonoids present in
propolis are considered to be rich source of chemopre-
ventive agents, since they have various therapeutic biolo-
gical activities such as immunomodulatory, anti-bacterial,
anti-viral, anti-fungal, anti-protozoal, anti-parasitic, anti-
inflammatory, anti-ulcer, anti-tumor anti-oxidant anti-
-proliferative, anti-mutagenesis, anti-angiogenic and anti-
allergic activities (10).
Significant progress has been exemplified by the trans-
lation of laboratory discovery correlating well with the
influence of chemopreventive natural products on exper-
imental tumors, heralding further advances in the near
future. In a recent review (10) we reported that propolis
and propolis-related polyphenolic compounds used as
cancer chemopreventive agents may play an important
role in prevention and therapy of experimental tumors in
vivo and in vitro. Chemoprevention is one of the most
promising new approaches in cancer research, i.e. the ad-
ministration of an agent to inhibit, delay or reverse the
process of carcinogenesis or inhibit proliferation of tu-
mor cells (11). The chemopreventive activity of propolis
and related polyphenolic/flavonoid compounds in ani-
mal tumor models and in in vitro cultures are likely to be
the result of their ability to inhibit DNA synthesis in tu-
mor cells, their capability to induce apoptosis of tumor
cells, and their property to activate macrophage to pro-
duce factors capable of regulating the function of B-, T-
and NK-cells, and direct toxicity to tumor cells (10).
In all, intravesical instillations with a chemothera-
peutic drug can clearly reduce the risk of recurrence for
patients with non-muscle-involved bladder carcinomas
in the short term (8). However, in the long term it has
only a modest effect on the risk of recurrence after TUR
without reducing the risk of progression. In case of high-
ly recurrent non-muscle-involved carcinoma or multiple
recurrences, the BCG therapy is advocated. Since pro-
polis preparations (WSDP or EEP) and propolis-related
polyphenolic/flavonoid components exerted strong anti-
tumor activity in in vitro cultures (10), we proposed that
their potential as an intravesical chemopreventive/che-
motherapeutic agent may prevent the recurrence rate of
transitional cell carcinoma directly by their direct cyto-
toxic action as well as indirectly by their antitumor activ-
ity described elsewhere (10). In addition to this, a com-
bined intravesical treatment and systemic use of propolis
and related flavonoids may in general have great impact
on transitional cell carcinoma since no toxicity or in-
duced side effects of propolis and related polyphenols re-
garding dose and the time of duration of treatment were
observed in experimental animals (10, 11).
This study was carried out to find whether propolis or
its polyphenolic/flavonoid compounds interfere with TCC
growth ability by induction of cytotoxicity in primary
culture of human urinary bladder carcinoma cells of dif-




There were 30 patients (10 grade G1, 10 grade G2,
and 10 grade G3 tumors). They were 65 to 75 years of
age. Patients were consecutive, not treated with any in-
travesical therapy and an informed consent for these
studies from each subject was obtained. In addition, the
performed studies were approved by local Human Inves-
tigation Committee.
Water-soluble derivative of propolis
(WSDP)
Water-soluble derivative of propolis (WSDP) was pre-
pared by the method described in our previous paper
(11). Briefly, Croatian propolis from beehives kept at the
outskirts of Zagreb was extracted with 96% ethanol which
was filtered and evaporated to dryness in vacuum evapo-
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rator. The resultant resinous product was added to a
stirred solution of 8% L-lysine (Sigma Chemie, Deisen-
hofer, Germany) and freeze-dried to yield the WSDP, a
yellow-brown powder.
The chemical profile of propolis from the northern
hemisphere, often named as »poplar-type« propolis can
be characterized by three analytical parameters: total
flavonol and flavone content, total flavanone and dihy-
droflavonol content, and total polyphenolics content. Ac-
cording to (12), spectrophotometric procedures for quan-
tification of the three main groups of bioactive substances
in propolis could be used for quality assessment of differ-
ent propolis samples, and results of those analyses corre-
late with biological activity, especially in the »poplar-
type« of propolis.The spectrophotometric assay based on
the formation of aluminum chloride complex was ap-
plied for quantification of total flavones/flavonols and
expressed as a quercetin equivalent. For the quantifica-
tion of propolis in flavanones and dihydroflavonols, we
used 2,4-dinitrophenylhydrazine method (13). Total poly-
phenolic content was measured by the Folin-Ciocalteu
procedure (14). WSDP contains: flavones and flavonols
2.13%, flavanones and dihydroflavonols 9.06%, total fla-
vonoids11.19%, total polyphenols 70.48%.
The WSDP was stored under sterile conditions at
-20°C to minimize bacterial contamination. Before use
the WSDP was dissolved in distilled water.
Ethanolic extract of propolis (EEP)
Raw Croatian propolis was collected by scraping it off
hive frames. The collected propolis samples were kept
desiccated in the dark until analysis at room tempera-
ture. Ethanolic propolis extract (EEP) was prepared by
the method described elsewhere (15). Briefly, propolis
(10 g) was crushed into small pieces in a mortar and
mixed vigorously with 34.85 ml 80% (V/V) ethanol dur-
ing 48 h at 37 ± 1 °C. After extraction, the ethanolic ex-
tract of propolis was filtered through Whatman N0.4
paper and then the extract was lyophilized. Recent spec-
trophotometric analysis has shown that EEP contains:
flavones and flavonols 1.6%, flavanones and dihydro-
flavonols 38.60%, total flavonoids 40.20, total polyphe-
nols 84.40%.
EEP was dissolved in ethanol and further dilutions
were made in water. The final concentration of ethanol
was less than or equal to 0.1%. Ethanol (0.1%) was used
in the control group.
Polyphenolic compounds
For experiments using polyphenolic compounds we
used Caffeic acid (CA) – 3,4-dihydroxycinnamic acid
(Aldrich-chemie, Milwaukee, WI, USA), Quercetin dihi-
dydrate (QU) (Fluka, BioChemica, Switzerland), Chry-
sin and Naringenin (Sigma, Germany).
All polyphenolic compounds were dissolved in etha-
nol and further dilutions were made in water. The final
concentration of ethanol was less than or equal to 0.1%.
Ethanol (0.1%) was also used in the control group. No
difference between water as control and 0.1% of ethanol
in water was observed in preliminary experiments.
Human tumour and normal epithelial
tissue samples
Pieces of urinary bladder TCC from the cavity of uri-
nary bladder or pieces of normal epithelial tissue from
urinary bladder wall were obtained with informed con-
sent from patients (General Hospital, Urology Depart-
ment, Vara`din, Croatia) and collected after surgical re-
section. Single cell suspension was prepared by digestion
with trypsin and DNase (11). Each suspension was pass-
ed through a stainless steel mash (200 wires/inch), cen-
trifuged three times at 24g for 5 minutes in saline and
then resuspended in medium RPMI-1640 (Institute of
Immunology, Zagreb) supplemented with 5% of fetal
calf serum (FCS). Viability was determined using trypan
blue exclusion assay. Percent of viability of bladder can-
cer cells was 69.23–94.8, 66.4–95.15 and 76.23–95.46 for
G1, G2, and G3, respectively.
Urinary bladder cancer-Pieces of urinary bladder TCC
from urinary bladder wall were collected by transure-
thral surgery from patients in different stages (grade G1,
G2, G3) of bladder TCC. The tissues were embedded in
paraffin and stained with hematoxylin and eosin for in-
vestigating the grade of carcinomas and the depth of in-
vasion in more detail. The criteria for histological grade
and clinical stage were as follows. Grade 1 (G1) indicates
well-differentiated tumors in cellular atypism and histo-
logical features as transitional epithelium. Grade 3 (G3)
indicates poorly differentiated tumors lacking in the fea-
tures of transitional epithelium. Grade 2 (G2) indicates
moderately differentiated tumors and medium features
between G1 and G3 (16). Samples of bladder cancer tis-
sue contained 95% transitional cell carcinoma cells as de-
termined by histochemical staining by Mallory method
and immunohistochemical staining by monoclonal anti-
body leukocyte common antigen (LCA), CD 68 and
S-100 proteins to exclude non tumor tissue components
(17).
Normal epithelial tissue-Pieces of normal epithelial tis-
sue from urinary bladder wall were taken from patients
by transurethral surgery.
Tumor- and normal epithelial-cell suspension-Single cell
suspension from pieces of either TCC cells or normal ep-
ithelial tissue from the urinary bladder was prepared ac-
cording to standard laboratory procedure (11).
Primary cell culture and reagents
Briefly, cells were seeded in triplicate in 24-well plates
(Falcon, USA) at a concentration of 1 x106 cells /ml for
TCC cells or normal epithelial cells. Incubation for cyto-
toxicity testing were carried out in RPMI-1640 medium
with 20% FCS at 37°C with 5% CO2 with or without dif-
ferent concentration (50, 150, 300 µg/ml) of test compo-
nents. The concentrations were selected based on result
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of pilot experiments, as described in our previous publi-
cations (10, 11, 18-20) as well as the experience related to
the work with propolis and flavonoids. After exposure to
test components for 24, 48, or 72 h, the cytotoxicity of two
propolis preparations (WSDP or EEP) and their poly-
phenolic compounds (caffeic acid, naringin, chrysin, and
quercetin) was determined using trypan blue exclusion
assay. Briefly, after cultivation, 100 µl of cell suspension
from the well was used and mixed with equal volume of
trypan blue. Following this procedure, the cells were
counted manually in a hemocytometer by three inde-
pendent observers.
Statistics
Differences between sample values were evaluated by
Student’s t test.
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Figure 1. Effect of propolis and its polyphenolic/flavonoid com-
pounds (300 µg/ml) on primary culture of human urinary bladder
transitional cell carcinoma cells in different histopathological stages.
Results are expressed as a percent of cytotoxicity from at least three tu-
mor samples in triplicate; the percentages of cytotoxicity cells were
obtained by substraction of treated and control samples. Statistical
significance was determined by using Student’s t test (*p<0.05;
**<0.1; ***<0.001).
Figure 2. Effect of propolis and its polyphenolic/flavonoid com-
pounds (150 µg/ml) on primary culture of human urinary bladder
transitional cell carcinoma cells in different histopathological stages.
Results are expressed as a percent of cytotoxicity from at least three tu-
mor samples in triplicate; the percentages of cytotoxicity cells were
obtained by substraction of treated and control samples. Statistical
significance was determined by using Student’s t test ((**p<0.1;
***<0.001).
Figure 3. Effect of propolis and its polyphenolic/flavonoid com-
pounds (75 µg/ml) on primary culture of human urinary bladder
transitional cell carcinoma cells in different histopathological stages.
Results are expressed as a percent of cytotoxicity from at least three tu-
mor samples in triplicate; the percentages of cytotoxicity cells were
obtained by substraction of treated and control samples. Statistical
significance was determined by using Student’s t test (*p<0.05;
**<0.1; ***<0.001).
RESULTS
Water and ethanolic extract of propolis
and its polyphenolic compounds inhibit
the growth of primary culture of human
urinary bladder TCC cells
Our first aim was to investigate whether treatment
with water or ethanolic extract of propolis or its poly-
phenolic compounds induce cytotoxic effect on primary
culture of human urinary bladder TCC cells. As shown
in Figures 1, 2 and 3, propolis and its polyphenolic com-
pounds induce cytotoxicity of primary culture of human
urinary bladder cancer cells in all histopathological gra-
des of cancer. Comparing the cytototoxic efficacy of test
components in different stages of urinary bladder TCC
cells, the greatest cytotoxicity was in G1 stage (Figures 1,
2, 3). Majority of test components exhibited a time- and
dose-dependent cytotoxicity (Figures 4, 5). Thus, WSDP
treatment at concentrations of 75, 150, and 300 mg/ml re-
sulted in 6-14% greater cytotoxicity than that in control tu-
mor cells in G2 histopathological cancer grade after 24 h; EEP
23.5–37.16%, CA 9.61–16.76%, naringin 3.76–22.66%,
chrysin 1.13–14.07% and QU 8.77–21.45%. In stage G3,
test components at doses of 75, 150, and 300 mg/ml in-
creased cytotoxicity to primary culture of human urinary
bladder TCC cells in relation of control tumor cells after
24 h incubation of primary culture in the following man-
ner: WSDP 0.25-25.71%, EEP 27.13-38.46%, CA 13.5–
18.18%, naringin 3.7-20%, chrysin 0-16.16%, and QU
22.22-40%, respectively. The most effective agent in these
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Figure 4. Dose-and time dependent effect of propolis and its polyphe-
nolic/flavonoid compounds on primary culture of human urinary
bladder transitional cell carcinoma cells in histopathological stage G2.
Results are expressed as a percent of cytotoxicity from at least three tu-
mor samples in triplicate; the percentages of cytotoxicity cells were ob-
tained by substraction of treated and control samples. Statistical signif-
icance was determined by using Student’s t test (*p<0.05; **<0.1).
Figure 5. Dose-and time dependent effect of propolis and its polyphe-
nolic/flavonoid compounds on primary culture of human urinary
bladder transitional cell carcinoma cells in histopathological stages
G3. Results are expressed as a percent of cytotoxicity from at least three
tumor samples in triplicate; the percentages of cytotoxicity cells were
obtained by substraction of treated and control samples. Statistical sig-
nificance was determined by using Student’s t test (*p<0.05; **<0.1;
***<0.001).
Figure 6. Comparative study of EEP on primary culture of human
urinary bladder transitional cell carcinoma cells in different histo-
pathological stages (G1, G2, G3) at concentration of 300 µg/ml. Re-
sults are expressed as a percent of cytotoxicity from at least three tumor
samples in triplicate; the percentages of cytotoxicity cells were obtained
by substraction of treated and control samples. Statistical signifi-
cance was determined by using Student’s t test (*p<0.05; **<0.1;
***<0.001).
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Figure 7. Primary culture of human urinary bladder transitional cell carcinoma cells: nontreated-control cells (A, B); urinary bladder carcinoma
cells treated with EEP (C), WSDP (D) quercetin (E) chrysin (F) after 72 hours. Primary culture of human urinary bladder transitional cell carci-
noma cells were photographed at x 400 magnification with a phase-contrast microscope.
Figure 8. Primary culture of human normal epithelial cells from urinary bladder wall: nontreated-control cells after 24 hours (A), 72 hours (B); nor-
mal epithelial cells treated with WSDP (C) or treated with EEP (D) after 72 hours. Primary culture of human normal epithelial cells were photo-
graphed at x 400 magnification with a phase-contrast microscope.
studies was EEP (Figures 6, 7). Test components exhib-
ited no cytotoxic effect on normal urinary bladder epi-
thelial cells (Figure 8).
DISCUSSION
This study is the first, according to the available litera-
ture, to demonstrate that treatment of primary culture of
human urinary bladder TCC cells with either prepara-
tion of water and/or ethanolic extract of propolis or with
their polyphenolic/flavonoid compounds caused direct
toxicity in vitro as compared to untreated control cells.
These results demonstrated that test components in-
duced time- and dose-dependent cytotoxicity on urinary
bladder TCC cells. The test components exhibited toxic-
ity on primary culture of human urinary bladder TCC
cells, and no toxicity to normal urinary bladder epithelial
cells. EEP was the most effective agent in these studies.
The percent (%) of cytototoxicity of EEP was reversible
to the histopathological cancer grade. Moreover, it is
likely that synergistic action of different flavonoids pres-
ent in EEP were more effective than any single com-
pound. These results are in line with our earlier studies
using animal cancer model (11, 18-20). In addition, the
cooperative action of different isoflavones on cell growth,
DNA synthesis, and apoptosis was also shown (21). Ike-
moto et al. (22) demonstrated the antitumor effect of
Scutellariae radix and its flavonoid components such as
baicalein, baicalin, and wogonin on human bladder can-
cer cell lines (KU-1 and EJ-19 and murine bladder can-
cer cell line (MBT-2). Authors showed that flavonoids
inhibited cell proliferation in dose-dependent manner,
but baicalin exhibited the greatest antiproliferative activ-
ity. The same authors in an in vivo experiment investigated
the antitumor effect of Scutellariae radix on C3H/HeN
mice with MBT-2 cells and demonstrated a significant
inhibition of tumor growth. Moreover, Yang et al. (23)
demonstrated the chemopreventive effect of two flavonoids
(diosmin and hesperidin) on N-butyl-N-(4-hydroxy-
butyl) nitrosamine (OH-BBN)-induced urinary-blad-
der carcinogenesis in male ICR mice. These authors
showed that hesperidin was more chemopreventive than
diosmin when mice were fed during the initiation stage.
This may be explained by differences in ring responsibil-
ity for anti-oxidant activity in flavonoids. Cell prolifera-
tion is thought to play an important role (24) in multi-
stage carcinogenesis, including bladder tumorigenes. The
result of the present study indicate that two preparations
of propolis (WSDP and EEP) and their polypheno-
lic/flavonoid components could effectively inhibit three
histopathological grades (G1, G2, G3) of human bladder
cancer. The greatest percent of cytotoxicity was in grade 1
(G1) while the effect of test components in grade 2 (G2)
or 3 (G3) was essentially similar; the somehow unusual
findings for grade G1 as opposed to grade G2 and G3
could be explained by heterogenicity of tumor cells which
in earlier phase of tumor growth is less expressed than in
the later phase (25). It is possible that propolis and its
flavonoids might induce cell differentiation as suggested
by Csokay et al. (26). Several biochemical targets have
been proposed to explain the cytotoxic effect of propolis
and its polyphenolic compounds, such as their antioxi-
dant properties to inhibit prooxidant enzymes (cyclo-
oxygenase, COX; lipooxygenase, LOX; xanthine oxi-
dase), inhibition of signal molecules, modulation activity
of oncogenes encouraging the process apoptosis/necro-
sis, a change of redox state of tumor cells, angiogenesis
inhibition and enzymes metalloproteinase, telomerase
and topoisomerase, ornithin decarboxilase, synthesis
polyamine, as well as numerous kinases (tyrosine protein
kinase, cAMP-dependent protein kinase, phosphoinosi-
tide 3-kinase, mitogen-activating protein kinase, cyclin-
dependent kinase) involved in cell proliferation (10, 26–
28). It also showed that the inhibition of prooxidative en-
zymes with flavonoids leads to inhibition of angiogenesis
process, and that it reduces the growth of human bladder
cancer in vitro by apoptotic mechanism (29–34). Pro-
polis, flavonoid galangin and other flavonoids from pro-
polis are potent COX-2 inhibitors among several natural
products tested (35-37). Therefore, it is possible that
galangin as a COX-2 inhibitor, as well as other fla-
vonoids present in propolis, may inhibit the proliferation
of urinary bladder cancer cells.
A large body of evidence suggests that inhibiting
COX-2, the inducible form of COX, will be an impor-
tant strategy for prevention of cancer. COX-2 overex-
pression has been observed in colorectal, non-small-cell
lung, gastric, breast, cervical, prostate and bladder cancer
(38–41), which is associated with an increase in angio-
genesis, tumor invasiveness, and immunosuppression in
various tumors along with decrease in apoptosis (42–46).
COX-2 inhibitors can also be expected to lead to efficacy
of their use as adjuncts to various anti-cancer agents (47).
The molecular mechanism of cancer chemoprevention
by flavonoids may involve the inhibition of the prooxi-
dant processes that cause tumor promotion. Flavonoids
and caffeic acid analogues are particularly effective at in-
hibiting the prooxidant enzymes xanthine oxidase (48,
49), COX or LOX (50). However, additional studies are
needed on the chemoprevention of urinary bladder can-
cer via this pathway.
Knowledge on various molecular chemopreventive or
therapeutic mechanisms that may be involved in the
mechanism of cancer chemoprevention by polypheno-
lic/flavonoid components was summarized in papers (10,
34, 51).
Moreover, inhibition of urinary bladder cancer by
green tee which contains polyphenolic catechin and other
components such as vitamin C, vitamin A, chlorophyll,
caffeine and quercetin (the components present in pro-
polis) was demonstrated in vitro and in vivo (16, 52, 53).
The incidence of bladder cancer has increased, and
responses to therapy have been limited. Several studies
have shown the effectiveness of immediate post-resec-
tion chemotherapy with agents such as doxorubicin and
mitomycin C (54, 55). Here we reported that water and/or
ethanolic extract of propolis or their polyphenolic/fla-
vonoid compounds may induce cytotoxicity in primary
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culture of human urinary bladder cancer cells and have
selective effect as compared to normal urinary bladder
epithelial cells. Although bacillus Calmette-Guerin is
one of the most effective agents for preventing recurren-
ce, it cannot be used immediately after resection secondary
to the systemic absorption. Propolis and its polyphe-
nolic/flavonoid components are not harmful if absorbed
and they reportedly do not affect normal tissue, making it
an ideal potential agent. Our previous data in vivo and
numerous literature data about chemopreventive mech-
anism and local effect of these components on tumor
cells (56) suggest that propolis and its compounds could
be potential candidates in therapy of urinary bladder
cancer. Widely available, safe and inexpensive, propolis
and its compounds may prove to be of considerable bene-
fit in the prevention and treatment of urinary bladder
cancer.
The result of this study may provide great impact on
the potential activity of EEP as an adjuvant to surgery, to
suppress or prevent tumor recurrence in urinary bladder
since only a few anti-cancer drugs have been effective in
tumor control. Since immunomodulation by BCG has
been used to improve the results of surgery it is likely that
propolis preparation (EEP) as immunomodulating
compound (57, 58) may be a substitute for mycobacterial
treatment as propolis preparation have expressed no side
effect after treatment. However, the exact cancer che-
moprevention mechanisms of propolis effectiveness have
to be elucidated. The data presented in this study also
support and warrant propolis efficacy studies in preclini-
cal urinary bladder models.
CONCLUSIONS
In conclusion, these results suggest that propolis and
its polyphenolic/flavonoid components may become at-
tractive and promising treatment for urinary bladder
cancer but further animal and human in vivo studies are
warranted to evaluate the safety and clinical utility of
these test components in patients with urinary bladder
cancer.
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